BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 24240044)

  • 1. Relation of interleukin-1β gene to treatment response in chronic patients infected with HCV genotype 4.
    Omran MH; Ibrahim NE; Youssef SS; Fatouh BE; Nabil W; El-Shami MM; El Awady MK
    J Infect Dev Ctries; 2013 Nov; 7(11):851-8. PubMed ID: 24240044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
    J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphism of low-density lipoprotein receptor did not affect treatment outcome of chronic hepatitis C genotype 3.
    Tanwandee T; Pithukpakorn M; Vipatakul N; Charatcharoenwitthaya P; Chainuvati S; Nimanong S; Prachayakul V; Pongprasobchai S; Manatsathit S; Leelakusolvong S; Pausawasdi N; Kachintorn U; Limwongse C; Udompunturak S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S147-53. PubMed ID: 21721440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Myxovirus Resistance Gene Promoter Polymorphism with Response to Combined Interferon Treatment and Progression of Liver Disease in Chronic HCV Egyptian Patients.
    Bader El Din NG; Salum GM; Anany MA; Ibrahim MK; Dawood RM; Zayed N; El Abd YS; El-Shenawy R; El Awady MK
    J Interferon Cytokine Res; 2015 Aug; 35(8):641-8. PubMed ID: 25868067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.
    Toyoda H; Kumada T; Shimada N; Takaguchi K; Ide T; Sata M; Ginba H; Matsuyama K; Izumi N
    J Med Virol; 2013 Jan; 85(1):65-70. PubMed ID: 23154876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C.
    Wasmuth HE; Werth A; Mueller T; Berg T; Dietrich CG; Geier A; Gartung C; Lorenzen J; Matern S; Lammert F
    Hepatology; 2004 Aug; 40(2):327-34. PubMed ID: 15368437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association with 5'-untranslated region and response to interferon in chronic hepatitis C.
    Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
    Hepatogastroenterology; 2007; 54(75):854-7. PubMed ID: 17591078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adiponectin changes in HCV-Genotype 4: relation to liver histology and response to treatment.
    Derbala M; Rizk N; Al-Kaabi S; Amer A; Shebl F; Al Marri A; Aigha I; Alyaesi D; Mohamed H; Aman H; Basem N
    J Viral Hepat; 2009 Oct; 16(10):689-96. PubMed ID: 19486470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection.
    Lehmann M; Meyer MF; Monazahian M; Tillmann HL; Manns MP; Wedemeyer H
    J Med Virol; 2004 Jul; 73(3):387-91. PubMed ID: 15170633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Soriano V; Núñez M; Sánchez-Conde M; Barreiro P; García-Samaniego J; Martín-Carbonero L; Romero M; González-Lahoz J
    Antivir Ther; 2005; 10(1):167-70. PubMed ID: 15751774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of interferon gamma and tumor necrosis factor-related apoptosis-inducing ligand receptor 1 single nucleotide polymorphism in natural clearance and treatment response of HCV infection.
    Azam S; Manzoor S; Imran M; Ashraf J; Ashraf S; Resham S; Ghani E
    Viral Immunol; 2015 May; 28(4):222-8. PubMed ID: 25798684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms of IL-10 gene in patients infected with HCV under antiviral treatment in southern Brazil.
    da Silva NM; Germano FN; Vidales-Braz BM; Carmo Zanella Rd; dos Santos DM; Lobato R; de Martinez AM
    Cytokine; 2015 Jun; 73(2):253-7. PubMed ID: 25797191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotype-related variations in proinflammatory and regulatory cytokine levels in treated and treatment-naive HCV-infected patients.
    Baharlou R; Romani B; Kiani SJ; Sadeghi K; Shadmand E; Fazel H; Jalilian FA; Kord E; Yaghoubi S; Nikmanesh Y; Ahmadi Vasmehjani A
    Med Microbiol Immunol; 2018 Feb; 207(1):65-74. PubMed ID: 29147974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammasome Genes' Polymorphisms in Egyptian Chronic Hepatitis C Patients: Influence on Vulnerability to Infection and Response to Treatment.
    Estfanous SZK; Ali SA; Seif SM; Soror SHA; Abdelaziz DHA
    Mediators Inflamm; 2019; 2019():3273645. PubMed ID: 30728751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.